Trial
NCT03693846
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Mucinous Adenocarcinoma of the Colon
Intervention
Nivolumab
Why stopped
Terminated due to slow enrollment and lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-20